Search for: [Abstract = "The solute carrier \(SLC\) group of membrane transport proteins are promising targets for treatment and studies of central nervous system \(CNS\) pathophysiology. Dysfunctions in CNS are related with deviation from homeostatic level of biogenic monoamines and gamma\-aminobutyric acid \(GABA\) concentrations. Such deviation are postuled as a neurological basis for several illnesses such as epilepsy, schizophrenia, insomnia, neuropathic pain or Parkinson disease. Firsts part of disertation briefly descripe biological basis and mechanism of monoamines and GABA reuptake as well as pharmaceutical acting along the same pathway. Among GABA reuptake inhibitors only tiagabine, a selective mGAT1 inhibitor, used for treatment of epilepsy. Discovery of novel inhibitors, which will have subtype selectivity for mGAT2\-mGAT4, may help in understanding of the structure and biological functions of these particular proteins. Well\-established strategies employed for design of small molecules acting on monoamine reuptake are focused on obtaining compounds that selectively block the action of dopamine transporter \(DAT\) or ones characterized by high affinity to dopamine transporter \(DAT\), noradrenaline transporter \(NET\) and serotonin transporter \(SERT\). Original results of research carried out by the author concern with those two targets. First, the work was directed towards obtaining small organic mole"]

Number of results: 1